Inclusion Criteria:

• male or female aged between 18 and 70

• capable of reading and understanding the information leaflet given to him/her

• signed an inform consent form

• presenting with idiopathic Parkinson's disease with a Hoehn and Yahr score of ≤ 3

• has never been given anti-Parkinson medication, or has been treated with L-Dopa, on condition that the total duration of treatment was less than twelve weeks at a dosage of under 200 mg, or has been treated with a dopamine agonist other than Pramipexole, on condition that:

  • either the patient is still in the dose-titration phase at the time of inclusion
  • or that the treatment was administered for less than six weeks and was completed two weeks before inclusion

Exclusion Criteria:

• women who are pregnant, breastfeeding, or planning a pregnancy in the months after joining the study
• women of reproductive age who have not undergone surgical sterilisation or who are not using a reliable method of contraception before joining the study and during the study
• patient presenting with hepatic insufficiency
• patient presenting with a concommitant illness which is considered significant by the investigator, after examination of the history, the patient's clinical condition, or on the basis on any additional examinations performed
• patient presenting with a skin lesion considered to be suspect by the investigator and which has not been evaluated by a dermatologist
• patient presenting with a contraindication to treatment with Rasagiline or Pramipexole (please see the SPC for the respective products)
• patient treated with fuoxetine during the five weeks preceding inclusion
• patient treated with fluvoxamine, pethidine, selegiline or any other MAOI during the two weeks preceding inclusion
• patient who has had deep brain stimulation treatment
• patient who might receive dextromethorphan or a sympathomimetic during the study